by Sneha Usakoyal
2 minutes
Lexeo Therapeutics Strengthens Leadership Team to Advance Cardiovascular and Rare Disease Initiatives
Dr. Sandi See Tai is stepping up as Chief Development Officer at Lexeo Therapeutics.
New York, USA – June 2024 – In a strategic move to fortify its leadership in developing cutting-edge treatments, Lexeo Therapeutics has announced significant changes to its executive team. Dr. Sandi See Tai is stepping up as Chief Development Officer to spearhead the company’s cardiovascular and rare disease portfolios. In parallel, Dr. Eric Adler has been named Chief Medical Officer & Head of Research, and Dr. Rajiv Patni takes on a pivotal role as Senior Advisor to the CEO and Board of Directors.
Dr. Sandi See Tai, whose expertise has been instrumental in advancing clinical trials at Lexeo, will now lead efforts to bring innovative therapies from the lab to the clinic. Her promotion underscores Lexeo’s commitment to addressing unmet medical needs in the cardiovascular and rare disease communities.
Dr. Eric Adler, who has been at the forefront of Lexeo’s research endeavors, will now oversee all medical and research operations. His deep understanding of the biotechnological landscape is expected to enhance the company’s research capabilities significantly.
Dr. Rajiv Patni’s new role as Senior Advisor will leverage his extensive experience in clinical strategy to provide strategic oversight and guidance at the executive level, ensuring alignment with the company’s long-term objectives.
“These leadership updates align perfectly with our mission to pioneer novel therapies,” said the CEO of Lexeo Therapeutics. “Drs. See Tai, Adler, and Patni bring a wealth of knowledge and a proven track record of leadership that is invaluable as we continue to navigate the complexities of biotech innovation.”
These appointments reflect Lexeo’s strategic approach to leadership in a highly competitive field, positioning the company to further its mission of delivering breakthrough treatments to patients who need them most.
For additional information about Lexeo Therapeutics and their projects, please visit Lexeo Therapeutics’ website.
